

Technology appraisal (TA)	Date of TA Release	Adherence of local formulary to NICE	
		Included on the Trust Formulary for this indication No Yes OR	Reason provided if "No"
<b>2021-22</b>			
<a href="#">TA782 - Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)</a>	30/03/2022	No	Terminated appraisal
<a href="#">TA781 - Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer</a>	30/03/2022	Yes	
<a href="#">TA780 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma</a>	24/03/2022	Yes	
<a href="#">TA779 - Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency</a>	16/03/2022	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA778 - Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria</a>	09/03/2022	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA777 - Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea</a>	09/03/2022	No	Not recommended
<a href="#">TA776 - Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea</a>	09/03/2022	No	Not recommended
<a href="#">TA775 - Dapagliflozin for treating chronic kidney disease</a>	09/03/2022	Yes	
<a href="#">TA774 - Lenalidomide for relapsed or refractory Mantle Cell Lymphoma</a>	09/03/2022	No	Terminated appraisal
<a href="#">TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction</a>	09/03/2022	Yes	
<a href="#">TA772 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies</a>	23/02/2022	Yes	
<a href="#">TA771 - Daratumumab with bortezomib, melphalan and prednisone for untreated Multiple Myeloma</a>	09/02/2022	No	Terminated appraisal
<a href="#">TA770 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer</a>	09/02/2022	Yes	
<a href="#">TA769 - Palforza for treating peanut allergy in children and young people</a>	02/02/2022	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA768 - Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs</a>	02/02/2022	Yes	
<a href="#">TA767 - Ponesimod for treating relapsing–remitting Multiple Sclerosis</a>	02/02/2022	Yes	
<a href="#">TA766 - Pembrolizumab for adjuvant treatment of completely resected stage 3 Melanoma</a>	02/02/2022	Yes	
<a href="#">TA765 - Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable</a>	02/02/2022	Yes	
<a href="#">TA764 - Fremanezumab for preventing migraine</a>	02/02/2022	Yes	
<a href="#">TA763 - Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable</a>	02/02/2022	Yes	
<a href="#">TA762 - Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy</a>	02/02/2022	No	Terminated appraisal
<a href="#">TA761 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection</a>	19/01/2022	Yes	
<a href="#">TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer</a>	12/01/2022	Yes	
<a href="#">TA759 - Fostamatinib for treating refractory chronic immune thrombocytopenia</a>	07/01/2022	No	Not recommended
<a href="#">TA758 - Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy</a>	05/01/2022	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA757 - Cabotegravir with rilpivirine for treating HIV-1</a>	05/01/2022	Yes	
<a href="#">TA756 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis</a>	16/12/2021	Yes	
<a href="#">TA755 - Risdiplam for treating spinal muscular atrophy</a>	16/12/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA754 - Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome</a>	15/12/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA753 - Cenobamate for treating focal onset seizures in epilepsy</a>	15/12/2021	Yes	
<a href="#">TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus</a>	15/12/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA751 - Dupilumab for treating severe asthma with type 2 inflammation</a>	08/12/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA750 - Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (Terminated appraisal)</a>	08/12/2021	No	Terminated appraisal
<a href="#">TA749 - Liraglutide for managing obesity in people aged 12 to 17 years (Terminated appraisal)</a>	25/01/2022	No	Terminated appraisal
<a href="#">TA748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders</a>	01/12/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases</a>	17/11/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer</a>	17/11/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA745 – NBTXR-3 for treating advanced soft tissue sarcoma</a>	10/11/2021	No	Terminated appraisal
<a href="#">TA744 - Upadacitinib for treating moderate rheumatoid arthritis</a>	10/11/2021	Yes	
<a href="#">TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease</a>	03/11/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations</a>	03/11/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer</a>	28/10/2021	Yes	
<a href="#">TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer</a>	28/10/2021	Yes	
<a href="#">TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable</a>	27/10/2021	Yes	
<a href="#">TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema</a>	20/10/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer</a>	20/10/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy</a>	20/10/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site

<a href="#">TA735 - Tofacitinib for treating juvenile idiopathic arthritis</a>	20/10/2021	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA734 - Secukinumab for treating moderate to severe plaque psoriasis in children and young people</a>	07/10/2021	Yes	
<a href="#">TA733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia</a>	06/10/2021	Yes	
<a href="#">TA732 - Baloxavir marboxil for treating acute uncomplicated influenza</a>	06/10/2021	No	Terminated appraisal
<a href="#">TA731 - Vericiguat for treating chronic heart failure with reduced ejection fraction</a>	29/09/2021	No	Terminated appraisal
<a href="#">TA730 - Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours</a>	29/09/2021	No	Terminated appraisal
<a href="#">TA729 - Sapropterin for treating hyperphenylalaninaemia in phenylketonuria</a>	22/09/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA728 - Midostaurin for treating advanced systemic mastocytosis</a>	22/09/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA727 - Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma</a>	22/09/2021	No	Terminated appraisal
<a href="#">TA726 - Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma</a>	22/09/2021	No	Terminated appraisal
<a href="#">TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</a>	15/09/2021	Yes	
<a href="#">TA724 - Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer</a>	08/09/2021	No	Not recommended
<a href="#">TA723 - Bimekizumab for treating moderate to severe plaque psoriasis</a>	01/09/2021	Yes	
<a href="#">TA 722 - Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement</a>	25/08/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA721 - Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer</a>	18/08/2021	No	Not recommended
<a href="#">TA720 - Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma</a>	18/08/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis</a>	21/07/2021	Yes	
<a href="#">TA718 - Ixekizumab for treating axial spondyloarthritis</a>	21/07/2021	Yes	
<a href="#">TA717 - Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)</a>	21/07/2021	No	Terminated appraisal
<a href="#">TA716 - Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency</a>	28/07/2021	Yes	
<a href="#">TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed</a>	14/07/2021	Yes	
<a href="#">TA714 - Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)</a>	14/07/2021	No	Terminated appraisal
<a href="#">TA713 - Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy</a>	07/07/2021	Yes	
<a href="#">TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer</a>	07/07/2021	Yes	
<a href="#">TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	30/06/2021	Yes	
<a href="#">TA710 - Ravulizumab for treating atypical haemolytic uraemic syndrome</a>	23/06/2021	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA709 - Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency</a>	23/06/2021	Yes	
<a href="#">TA708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis</a>	23/06/2021	Yes	
<a href="#">TA707 - Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer</a>	15/06/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA706 - Ozanimod for treating relapsing-remitting multiple sclerosis</a>	09/06/2021	No	Not recommended
<a href="#">TA705 - Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer</a>	02/06/2021	Yes	
<a href="#">TA704 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies</a>	26/05/2021	Yes	
<a href="#">TA703 - Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)</a>	26/05/2021	No	Terminated appraisal
<a href="#">TA702 - Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)</a>	26/05/2021	No	Terminated appraisal
<a href="#">TA701 - Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)</a>	19/05/2021	No	Terminated appraisal
<a href="#">TA700 - Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)</a>	19/05/2021	No	Terminated appraisal
<a href="#">TA699 - Ofatumumab for treating relapsing multiple sclerosis</a>	19/05/2021	Yes	
<a href="#">TA698 - Ravulizumab for treating paroxysmal nocturnal haemoglobinuria</a>	19/05/2021	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA697 - Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban</a>	12/05/2021	Yes	
<a href="#">TA696 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy</a>	12/05/2021	No	Not recommended
<a href="#">TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma</a>	28/04/2021	Yes	
<a href="#">TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia</a>	28/04/2021	Yes	

<a href="#">TA693 - Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer.</a>	28/04/2021	<b>No</b>	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy.</a>	28/04/2021	<b>No</b>	Not recommended
<a href="#">TA691 - Avelumab for untreated metastatic Merkel cell carcinoma.</a>	21/04/2021	<b>Yes</b>	
<a href="#">TA690 - Teduglutide for treating short bowel syndrome (terminated appraisal).</a>	21/04/2021	<b>No</b>	Terminated appraisal